Suhui Yang

Prof. Dr. Suhui Yang

Charles R. Drew University of Medicine and Science
+1
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2021 in Cancer Research
Verified
Journal Article
Open access
PDF file
SSSoma Samanta
Soma Samanta
Suhui YangSuhui Yang
Suhui Yang
BDBikash Debnath
Bikash Debnath
DXDing Xue
Ding Xue
YKYuting Kuang
Yuting Kuang
NNNouri Neamati
Nouri Neamati
GRP78 (glucose-regulated protein, 78 kDa) is a key regulator of endoplasmic reticulum (ER) stress signaling. Cancer cells are highly proliferative and have high demand for protein synthesis and folding, which results in significant stress on the ER. To respond to ER stress and maintain cellular homeostasis, cells activate the unfolded protein response (UPR) that promotes either survival or apoptotic death. Cancer cells utilize the UPR to promote survival and growth. In this study, we describe the discovery of a series of novel hydroxyquinoline GRP78 inhibitors. A representative analogue, YUM70, inhibited pancreatic cancer cell growth in vitro and showed in vivo efficacy in a pancreatic cancer xenograft model with no toxicity to normal tissues. YUM70 directly bound GRP78 and inactivated its function, resulting in ER stress–mediated apoptosis. A YUM70 analogue conjugated with BODIPY showed colocalization of the compound with GRP78 in the ER. Moreover, a YUM70-PROTAC (proteolysis targeting chimera) was synthesized to force degradation of GRP78 in pancreatic cancer cells. YUM70 showed a strong synergistic cytotoxicity with topotecan and vorinostat. Together, our study demonstrates that YUM70 is a novel inducer of ER stress, with preclinical efficacy as a monotherapy or in combination with topoisomerase and HDAC inhibitors in pancreatic cancer. Significance: This study identifies a novel ER stress inducer that binds GRP78 and inhibits pancreatic cancer cell growth in vitro and in vivo, demonstrating its potential as a therapeutic agent for pancreatic cancer.

1 January 2019 in Theranostics
Verified
Journal Article
Open access
SXShili Xu
Shili Xu
YLYajing Liu
Yajing Liu
KYKai Yang
Kai Yang
HWHanxiao Wang
Hanxiao Wang
ASAndrea Shergalis
Andrea Shergalis
NNNouri Neamati
Nouri Neamati
Aberrant overexpression of endoplasmic reticulum (ER)-resident oxidoreductase protein disulfide isomerase (PDI) plays an important role in cancer progression. In this study, we demonstrate that PDI promotes glioblastoma (GBM) cell growth and describe a class of allosteric PDI inhibitors that are selective for PDI over other PDI family members.

13 February 2019 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Suhui YangSuhui Yang
Suhui Yang
ASAndrea Shergalis
Andrea Shergalis
DLDan Lu
Dan Lu
AKAnahita Kyani
Anahita Kyani
ZLZiwei Liu
Ziwei Liu
NNNouri Neamati
Nouri Neamati

31 January 2022 in Cancers
Verified
Journal Article
Open access
PDF file
Suhui YangSuhui Yang
Suhui Yang
CJChanel Jackson
Chanel Jackson
EKEduard Karapetyan
Eduard Karapetyan
PDPranabananda Dutta
Pranabananda Dutta
DKDulcie Kermah
Dulcie Kermah
JVJay Vadgama
Jay Vadgama
Protein disulfide isomerase (PDI) is the endoplasmic reticulum (ER)’s most abundant and essential enzyme and serves as the primary catalyst for protein folding. Due to its apparent role in supporting the rapid proliferation of cancer cells, the selective blockade of PDI results in apoptosis through sustained activation of UPR pathways. The functions of PDI, especially in cancers, have been extensively studied over a decade, and recent research has explored the use of PDI inhibitors in the treatment of cancers but with focus areas of other cancers, such as brain or ovarian cancer. In this review, we discuss the roles of PDI members in breast cancer and PDI inhibitors used in breast cancer research. Additionally, a few PDI members may be suggested as potential molecular targets for highly metastatic breast cancers, such as TNBC, that require more attention in future research.

1 February 2020 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
JHJinhe Han
Jinhe Han
HLHye Won Lee
Hye Won Lee
YJYifeng Jin
Yifeng Jin
DKDaulat B. Khadka
Daulat B. Khadka
Suhui YangSuhui Yang
Suhui Yang
WCWon-Jea Cho
Won-Jea Cho

1 October 2020 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
XLXiaoli Li
Xiaoli Li
JHJinhe Han
Jinhe Han
HLHye Won Lee
Hye Won Lee
YYYi-Seul Yoon
Yi-Seul Yoon
YJYifeng Jin
Yifeng Jin
WCWon-Jea Cho
Won-Jea Cho